Bronchiectasis

July 2, 2014November 6, 2015

Study Reveals That Adherence To Treatment Affects Health Outcomes in Patients With Bronchiectasis

Bronchiectasis, News

A group of researchers from Queen’s University in Belfast, United Kingdom, recently published a study aiming to determine the level of adherence to inhaled antibiotics, other respiratory medicines and airway ... Read more

July 1, 2014November 6, 2015

Bayer Gains Orphan Drug Status For Ciprofloxacin To Treat Non Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Bayer HealthCare’s Ciprofloxacin Dry Powder for Inhalation, a treatment for non-cystic fibrosis bronchiectasis (NCFB), was recently granted orphan drug designation by the U.S Food and Drug Administration’s (FDA) Office of Orphan ... Read more

June 4, 2014November 6, 2015

Aradigm Receives $5 Million for the First Patient to Test Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation has received a $5 million milestone payment from Grifols S.A. for dosing of the first patient in a phase III study of the ORBIT-3 (once-daily respiratory bronchiectasis inhalation ... Read more

May 27, 2014November 6, 2015

New Phase 3 Trial Tests Therapy For Non-Cystic Fibrosis Bronchiectasis Exacerbations On Patients In China

Bronchiectasis, News

Jinmimg Gao, a Professor of Oncology and Pharmacology in the Department of Pharmacology, Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, is the principal investigator of a Phase-3 clinical ... Read more

May 27, 2014November 6, 2015

FDA Grants Orphan Status To Edmond Pharma’s Bronchiectasis Drug

Bronchiectasis, News

The Food and Drug Administration (FDA) has granted Italian pharmaceutical company Edmond Pharma with the Orphan Drug Designation for their mucoactive drug Erdosteine, a therapy used for the treatment of bronchiectasis. According ... Read more

May 22, 2014November 6, 2015

Non-Cystic Fibrosis Bronchiectasis Drug Pulmaquin Receives QIDP Designation From FDA

Bronchiectasis

Aradigm Corporation’s experimental therapy Pulmaquin, an inhaled antibiotic for the treatment of non-cystic fibrosis bronchiectasis, was recently given the Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). The ... Read more